Julio Licinio, MD, PhD, MBA, MS, is a renowned psychiatrist and an internationally recognized research leader in neuroscience, stress, pharmacogenomics, microbiome, and depression. He is the inaugural Editor-in-Chief (EIC) of Genomic Psychiatry. 

Dr. Licinio is a board-certified psychiatrist by the American Board of Psychiatry and Neurology, and he is a Fellow of the Royal Australian and New Zealand College of Psychiatrists (FRANZCP) and a Fellow of the Australian Academy of Health and Medical Sciences (FAAHMS). Dr. Licinio has published 327 research papers listed in Pubmed. His work has been cited 42,166 times, and his h-index is 90.

In his career spanning over 30 years, Dr. Licinio has founded and led four journals from inception to full indexing and high impact. He has edited and published 44 articles by 9 Nobel Prize laureates in the last seven years alone, including 19 by the late Nobel laureate Paul Greengard. Dr. Licinio is a seasoned Editor-in-Chief, having raised the impact factor and rankings of the first journal he launched, which went from non-existent to number 1 worldwide in just 13 years.

Our Editorial Board has eminent international experts. Confirmed members of the Editorial Board include:

Huda Akil, University of Michigan, Ann Arbor, Michigan 48109, USA

Ole A. Andreassen, University of Oslo, 0318 Oslo, Norway

Bernhard Baune, University of Münster, 48149 Münster, Germany 

Stefan R. Bornstein, TUD Dresden University of Technology, 01307 Dresden, Germany  

Kristen Brennand, Yale University School of Medicine, New Haven, Connecticut 06511, USA 

Avshalom Caspi, Duke University, Durham, North Carolina 27708, USA

Moses Chao, New York University Langone Medical Center, New York, New York 10016, USA

Claude Robert Cloninger, Washington University School of Medicine, St. Louis, Missouri 63110, USA. 

Ian Deary, University of Edinburgh, Edinburgh, EH8 9JZ, Scotland, UK

Yogesh Dwivedi, University of Alabama at Birmingham, Birminagm, Alabama 35294, USA

Janice Fullerton, Neuroscience Research Australia and University of New South Wales, Randwick, NSW 2031, Australia

Fred H. Gage, Salk Institute for Biological Studies, La Jolla, California 92037, USA                                   

Samuel E. Gandy, Icahn School of Medicine at Mount Sinai, New York, New York 10029-5674, USA

Patricia Gaspar, INSERM Paris Brain Institute, Hôpital Salpêtrière, 75013 Paris, France

Anthony A. Grace, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, USA

Todd D. Gould, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA     

Raquel E. Gur, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA          

Jan-Åke Gustafsson, University of Houston, Houston, Texas 77204, USA    

Sir John Hardy, University College London Dementia Research Institute, London, WC1E 6B, UK

Noboru Hiroi, University of Texas Health San Antonio, San Antonio, Texas 78229, USA

Yasmin Hurd, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA

Siegfried Kasper, Center for Brain Research, Medical University of Vienna, 1090 Vienna, Austria

Kenneth S. Kendler, Virginia Commonwealth University, Richmond, Virginia 23298, USA     

Lorenzo Leggio, National Institutes of Health, Baltimore, Maryland 21224, USA   

Xin-Yun Lu, Medical College of Georgia at Augusta University, Augusta, Georgia 30912, USA

Robert Malenka, Stanford University, Stanford, California 94305, USA

Andrew McIntosh, University of Edinburgh, Edinburgh, EH10 5HF, Scotland, UK,

Maria Oquendo, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA              

Sir Michael Owen, Cardiff University, Cardiff, CF24 4HQ, Wales, UK

Aarno Palotie, Institute for Molecular Medicine, University of Helsinki, 00014 Helsinki, Finland

Carlos N. Pato, Rutgers University, Piscataway, New Jersey 08854, USA

Michele Pato, Rutgers University, Piscataway, New Jersey 08854, USA

Mary L. Phillips, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA

Robert Plomin, Institute of Psychiatry Psychology and Neuroscience at King’s College London, SE5 8AF, UK

Maurizio Popoli, Università degli Studi di Milano, 20133 Milan, Italy                                      

John Rubenstein, University of California, San Francisco, California 94158, USA

Carlo Sala, L’ Istituto di Neuroscienze del CNR, Università degli Studi di Milano – Bicocca, 20854 Vedano al Lambro, MB, Italy

Alan F. Schatzberg, Stanford University, Stanford, California 94305, USA

Jair Soares, University of Texas Health Science Center, McGovern School of Medicine, Houston, Texas 77054, USA

Thomas C. Südhof, Stanford University, Stanford, California 94305, USA

Giuseppe Testa, Università degli Studi di Milano, Human Technopole, 20157, Milan, MI, Italy

Gustavo Turecki, McGill University, Montréal, Québec H4H 1R3, Canada

Monica Uddin, University of South Florida, Tampa, Florida 33612, USA

Myrna Weissman, Columbia University Vagelos College of Physicians and Surgeons, New York State Psychiatric Institute, New York, New York 10032, USA

Xiangmin Xu, University of California, Irvine, California 92697, USA  

Takeo Yoshikawa, RIKEN Brain Science Institute, Saitama, 351-0198, Japan                                    

Mone Zaidi, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA

1. Journal Overview

Genomic Psychiatry: Advancing Science from Genes to Society (Genomic Psychiatry) is a pioneering journal that interweaves groundbreaking advances in psychiatric genomics with major advances in all other areas of contemporary psychiatry. We recognize that the impact of genes in psychiatry is modified by development, environment, and society, while conversely, environmental and societal factors interact with our genetic substrate before their effects are manifested.

2. Aims & Scope

The principal aim of Genomic Psychiatry is to interweave groundbreaking advances in psychiatric genomics with major advances in all other areas of contemporary psychiatry. Why is this important? The impact of genes in psychiatry is clearly modified by development, the environment, and society. Conversely, the environment and society interact with our genetic substrate before their effects are manifested. By bringing together, side by side, single contributions and interdisciplinary collaborations from genomics and multiple other fields, Genomic Psychiatry aims to redefine psychiatric science by bringing about a veritable transformation on how we bring together progress in genomics and all other fields to enhance our understanding of psychiatric disorders, from genes to society.

Genomic Psychiatry has a broad scope. As our goal is to interweave genetics with other advances in contemporary psychiatry, we welcome innovative research from in-depth studies of psychiatric genomics to broader investigations of the underpinnings, treatments, outcomes, and consequences of mental health. In addition to the genetic aspects of mental illness, our scope includes advances in neuroscience of potential relevance to mental illness, imaging, psychology, pharmacology, therapeutics, microbiology including the microbiome, immunology, endocrinology, brain stimulation, functional neurosurgery, "big data," computational approaches including AI, epidemiology, and public health initiatives.

Article Types

Genomic Psychiatry accepts 28 different article types to accommodate the full spectrum of psychiatric genomics research and scholarship. From traditional original research articles and comprehensive reviews to innovative formats like data reports, study protocols, and multimedia presentations, we provide authors with the flexibility to choose the format that best suits their work. Complete descriptions of all article types and their requirements are available in our Author Instructions.

3. Open Access Statement

Genomic Psychiatry is a fully Open Access journal committed to the immediate, free dissemination of scientific knowledge.

We publish all content under the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Articles published prior to June 17, 2025 were published under CC BY-NC-ND 4.0; however, all new submissions are published under the more permissive CC BY 4.0 license (https://creativecommons.org/licenses/by/4.0/deed.en). This means:

• Immediate free access: All articles are freely available to read, download, and share immediately upon publication
• No subscription barriers: No login requirements or paywalls restrict access to our content
• Reuse rights: Readers may copy, distribute, transmit, and adapt the work for any purpose, including commercial use, with proper attribution
• Author retention of copyright: Authors retain copyright of their work while granting the journal the right to publish
• Global accessibility: Our content is accessible worldwide without geographic or institutional barriers
• Machine readability: Full-text articles are available in formats suitable for text mining and computational analysis
• Permanent access: All published content remains freely accessible in perpetuity

This Open Access model ensures that research findings reach the widest possible audience, including researchers, clinicians, policymakers, patients, and the general public, thereby maximizing the impact and utility of published work.

Complete information about our Open Access policy is available at https://genomicpress.kglmeridian.com/view/journals/genpsych/genpsych-overview.xml/about

4. Mission and Values

Our mission is to push the frontiers of knowledge across the continuum from the genome to society, interweaving progress in genomics with advances in all other areas of psychiatry. Through our discovery and innovation journey, we aim at creating a new, cross-disciplinary, and team-science based narrative for mental health in the genomic era. We are particularly committed to work that is conceptually novel and that has the potential for translational impact.

Genomic Psychiatry values integrity, scientific rigor, ethical standards, and inclusivity. We welcome papers from all countries and all continents and will treat and process each manuscript based exclusively on its content, not on where it comes from.

5. Research Impact and Visibility

Genomic Psychiatry publishes high-impact research that consistently receives exceptional attention from both the scientific community and global media. Our articles have been featured in major international news outlets, demonstrating their relevance and importance to global public health and scientific advancement.

Multiple publications in Genomic Psychiatry have achieved extraordinary recognition. For example, our breakthrough study on early infant brain development was covered by major outlets across the United States and Australia, including Fox affiliates, CBS, NBC, and specialized medical and neuroscience news platforms. The research has been indexed across multiple academic search engines and databases, demonstrating its significant impact on the field.

This pattern of extensive media coverage and academic attention firmly establishes Genomic Psychiatry as an important international forum for disseminating critical developments in psychiatric genomics and mental health research. Our content demonstrates substantial real-world impact through extensive media coverage and influence on mental health policy and practice. This strong public engagement complements our commitment to publishing scientifically rigorous research from leading international researchers that addresses pressing questions in psychiatric genomics.

6. Article-Level Metrics and Impact Tracking (Altmetric)

Genomic Psychiatry provides comprehensive metrics for all published articles through our partnership with Altmetric, a leading provider of alternative metrics that track the online attention and engagement surrounding scholarly research.

Altmetric Integration

Every article published in Genomic Psychiatry receives an Altmetric badge that visually represents the online attention it has received. These distinctive, colorful "donuts" appear on all article pages and provide:

• Real-time tracking of mentions across diverse sources including news media, social media platforms, policy documents, patents, and scholarly blogs
• Detailed breakdowns showing where and how research is being discussed, shared, and used beyond traditional citations
• Geographic reach displaying the global distribution of attention to published research
• Attention scores that help authors, institutions, and readers quickly assess the broader impact and public engagement with research

This integration complements traditional citation metrics by capturing the immediate societal impact and public engagement with research published in Genomic Psychiatry, demonstrating how our articles contribute to public discourse, policy discussions, and knowledge dissemination beyond the academic community.

Authors can track their article's performance in real-time, and institutions can monitor the broader impact of their researchers' work, making Genomic Psychiatry an attractive venue for researchers seeking maximum visibility and engagement for their findings.

7. Governing Body and Editorial Structure

Genomic Psychiatry is guided by an exceptionally distinguished Editorial Board comprising 50 internationally recognized experts in psychiatric genomics, neuroscience, psychiatry, and related fields from prestigious institutions worldwide. Our Editorial Board includes Nobel Prize Laureate Thomas C. Südhof and numerous members of the world's most prestigious scientific academies.

Academy Members and Honors

Our Editorial Board's distinction includes:

• US National Academy of Sciences: Huda Akil, Moses Chao, Fred Gage, Jan-Åke Gustafsson, Yasmin Hurd, Robert Malenka, John Rubenstein, and Thomas Südhof
• US National Academy of Medicine: Fred Gage, Raquel Gur, Yasmin Hurd, Kenneth Kendler, Robert Malenka, Maria Oquendo, John Rubenstein, Alan Schatzberg, Thomas Südhof, Gustavo Turecki, and Myrna Weissman
• The Royal Society: Jonathan Flint and John Hardy as Fellows
• British Knighthoods: Sir John Hardy and Sir Michael Owen, recognized by the British monarchy for their extraordinary achievements

This broad, diverse, and highly accomplished group represents institutions including Stanford University, Yale University, University of Michigan, Duke University, University of Edinburgh, University College London, INSERM Paris, University of Oslo, and many other world-renowned research centers across North America, Europe, Asia, and Australia.

The exceptional caliber of our Editorial Board ensures comprehensive expertise across the entire spectrum of psychiatric genomics and related disciplines, from molecular genetics to clinical psychiatry and public health. This global network of leading researchers helps Genomic Psychiatry attract high-quality submissions from around the world and provides expert peer review across all areas of psychiatric genomics and mental health research.

The complete list of Editorial Board members and their affiliations is available at https://genomicpress.kglmeridian.com/view/journals/genpsych/genpsych-overview.xml?journal-tabs-desktop=Editorial+Board

8. Peer Review Process

Peer review stands as the foundational pillar of the scientific evaluation process, extensively employed in the assessment of research funding (grants) and research outcomes (papers). Our unwavering commitment resides in upholding the integrity of the editorial process, which rests upon an impartial peer review system.

Genomic Psychiatry adheres to the traditional single-blind peer review format, which is the most widely used. In this process, reviewers know the authors' identities, but authors do not know their reviewers' identities. This approach helps reviewers make informed assessments while protecting reviewer anonymity.

Every submission to Genomic Psychiatry, encompassing original research, reviews, correspondence, and all manuscript genres, will invariably undergo external evaluation via single-blind peer review. The only exception to the peer review process consists of purely informational material, such as news and editorials, which are explicitly identified as such.

Review Timeline

We are committed to providing timely peer review while maintaining rigorous standards. Authors can typically expect initial editorial decisions within 2-4 weeks of submission. This efficient review process ensures that important research reaches the scientific community promptly while maintaining the thoroughness necessary for high-quality peer review. The total average time from submission to publication is 45 days for Genomic Psychiatry.

To ensure the global diversity of Genomic Psychiatry, each submission is typically sent to eight experts, strategically selected to avoid concentration in any single country. Our editorial decisions aim to be grounded in at least three reviews, although if only two reviews are available, they will be considered in the decision-making process.

9. Publication Ethics and Scientific Integrity

At Genomic Psychiatry, scientific integrity is our cornerstone. We uphold the highest standards of scientific excellence through complete transparency and uncompromising honesty. As part of our commitment to publication ethics:

Ethical Guidelines

• All papers undergo rigorous peer review (see above)
• All submissions are screened for plagiarism of text, figures, and images
• We maintain clear policies regarding conflicts of interest, requiring disclosure from all authors, reviewers, and editors
• We follow ethical guidelines for research involving human subjects and animals
• We adhere to best practices for authorship attribution and credit

Complete information about our plagiarism screening policy is available at https://genomicpress.kglmeridian.com/view/journals/genpsych/genpsych-overview.xml/about

Misconduct Investigation

We take potential misconduct seriously while recognizing the limitations of a journal's role in such matters. When concerns about potential misconduct arise, our approach is measured and procedural:

1. Initial inquiries are directed to the corresponding author, seeking clarification on questioned issues
2. If author explanations are insufficient or concerns persist, we may contact all co-authors to ensure awareness
3. For unresolved concerns, we notify the authors' institution(s) so that a formal institutional inquiry can be conducted, as journals cannot compel authors to provide original data or conduct formal investigations
4. We cooperate with institutional investigations while respecting their authority in addressing potential misconduct by their researchers

This balanced approach respects both the need for scientific integrity and the appropriate roles of journals versus research institutions in addressing misconduct concerns.

Publication Corrections

When correcting the published record, we take a contextual approach:

• Issuing errata for honest errors that do not impact overall conclusions
• Reserving retractions for cases involving misconduct, errors that undermine findings, extensive plagiarism, or overall loss of confidence in the work

While we largely align with the Committee on Publication Ethics (COPE) guidelines, we maintain flexibility to take different approaches when circumstances require. This may involve communicating with authors' institutions, funders, or other relevant oversight bodies to enable thorough investigations.

Appeals and Complaints Process

Authors who wish to appeal editorial decisions or lodge complaints about the peer review process should follow these procedures:

1. Initial Appeal: Submit a detailed appeal letter to the Editor-in-Chief via support@genomicpress.com within 30 days of the decision, explaining why the decision should be reconsidered
2. Review Process: Appeals are reviewed by the Editor-in-Chief, who may, at their discretion, consult with relevant Editorial Board members who were not involved in the original decision
3. Timeline: Authors can expect a response to appeals within 2-3 weeks
4. Final Decision: The Editor-in-Chief's decision on appeals is final
5. Complaints: For complaints about editorial processes, ethics, or other concerns, contact support@genomicpress.com. All complaints are investigated thoroughly and addressed within 21 days

Data Sharing and Reproducibility Policy

To promote transparency and reproducibility in research:

1. Data Availability Statement: All manuscripts must include a data availability statement describing where supporting data can be found
2. Encouraged Practices: Authors are strongly encouraged to:
   • Deposit raw data in appropriate public repositories (e.g., GEO, dbGaP, Dryad, Figshare)
   • Share analysis code and scripts via GitHub or similar platforms
   • Provide detailed methods to enable replication
3. Minimum Requirements: At minimum, authors must make available:
   • Data underlying all figures and tables
   • Custom code or algorithms essential to the conclusions
   • Detailed protocols for novel methods
4. Exceptions: Restrictions may apply for patient privacy, proprietary data, or ethical constraints, which must be clearly stated
5. Materials Sharing: Authors must agree to share unique materials (e.g., antibodies, cell lines, constructs) with qualified researchers upon reasonable request

Post-Publication Discussion Policy

We encourage scholarly discourse and maintain the integrity of the published record:

1. Letters to the Editor: Readers may submit letters commenting on published articles within 6 months of publication
2. Author Response: Original authors are invited to respond to substantive criticisms
3. Post-Publication Review: We welcome post-publication peer review via established platforms (e.g., PubPeer)
4. Social Media: Authors and readers are encouraged to discuss articles on social media using article DOIs

10. Publishing Schedule and Access

Print Edition

• ISSN: 2997-254X
• First Print Issue: January 2025
• Publication Frequency: Every two months

Online Edition

• ISSN: 2997-2388
• Early Online Release: Began January 2024
• Availability: Open Access
• Publication Type: Postpub

Genomic Psychiatry began with Early Online Release articles in January 2024, followed by our first formal print issue in January 2025. We have maintained our bi-monthly publication schedule with the January, March, and May 2025 issues already published and our July 2025 issue currently in production. Articles are made available online immediately upon final acceptance and production, with our content accessible through our dedicated website in an Open Access format.

11. Indexing Status and Publication Information

Genomic Psychiatry is registered with Crossref, providing all publications with searchable DOI links. Our DOI prefix is 10.61373.

The journal is indexed with the US Library of Congress, Scilit, and Google Scholar, ensuring our published research receives broad visibility in academic searches.

The journal has been assigned NLM ID 9919033201306676 and is listed in the NLM catalog, demonstrating our commitment to meeting MEDLINE standards.

PubMed Central Compliance

Genomic Psychiatry supports authors in meeting funder mandates for public access. While we are actively pursuing full MEDLINE/PubMed indexing, authors can currently deposit their accepted manuscripts in PubMed Central (PMC) to comply with NIH and other funding agency requirements. Successfully deposited manuscripts appear in PubMed with the designation "Author Manuscript" and receive PubMed IDs (PMIDs). For example, PMID 40469939 represents a Genomic Psychiatry article currently accessible through this mechanism.

As a scholarly-driven publication, we are actively pursuing indexing in additional respected databases, including Medline/PubMed/Index Medicus, Scopus, Embase, and Clarivate (including Emerging Sources Citation Index, Journal Citation Reports and Web of Science). We are implementing an indexing strategy that will lead to inclusion in these platforms upon meeting their requirements, making prior submissions accessible retrospectively through those databases. We are taking all necessary measures to meet MEDLINE selection criteria and anticipate applying for full indexing in the near future.

12. Archiving and Long-term Preservation

Genomic Psychiatry is committed to ensuring permanent access to all published research through our partnership with Portico, a leading digital preservation service. We have recently deposited all our published issues with Portico, guaranteeing that our content will remain accessible to the scholarly community for generations to come.

About Portico

Portico is a community-supported digital preservation service that has been safeguarding scholarly content since 2005. As part of ITHAKA---a nonprofit organization dedicated to expanding access to knowledge and education worldwide---Portico serves as a trusted guardian of digital scholarship for over 1,000 publishers and 1,000 libraries globally.

Key features of Portico preservation:

• Certified Trustworthy Repository: Portico has been certified by the Center for Research Libraries as a Trustworthy Digital Repository, confirming that its practices meet the highest standards set by the preservation community
• Dark Archive Protection: Portico operates as a "dark archive," meaning content is preserved securely and made accessible if specific trigger events occur, ensuring uninterrupted access to research
• Triple Redundancy: Content is preserved in three geographically distributed locations for maximum security and protection against any form of data loss
• Format Migration: Portico continuously monitors and migrates content to new formats as technology evolves, ensuring your research remains accessible regardless of future technological changes
• Perpetual Access: Our partnership with Portico guarantees that all Genomic Psychiatry content will remain available to researchers, students, and scholars indefinitely, supporting the continuity of scientific knowledge

This comprehensive preservation strategy demonstrates our commitment to the long-term stewardship of the research we publish, ensuring that the important work appearing in Genomic Psychiatry will continue to contribute to scientific progress for decades to come.

13. Copyright and Licensing Policies

Genomic Psychiatry maintains clear copyright and licensing policies that are accessible to all authors and readers. All published articles clearly indicate the copyright holder. As an Open Access journal, we publish content under a Creative Commons license, with specific terms clearly stated on each published article in both HTML and PDF formats.

Our website provides detailed author guidelines that include complete information about our copyright policies, licensing terms, and any requirements regarding the posting of final accepted versions or published articles on third-party repositories. Complete information about our copyright and licensing policies is available at https://genomicpress.kglmeridian.com/view/journals/genpsych/genpsych-overview.xml/about

14. Author Fees and Revenue Sources

Genomic Psychiatry operates on an Article Processing Charge (APC) business model, with all revenue generated through these publication fees. Our APC structure provides the financial foundation for our high-quality peer review, production, and publication processes while maintaining our Open Access status.

Complete information regarding our APC rates is clearly stated on our website in a location that is easily accessible to potential authors prior to manuscript submission. We maintain full transparency about our funding model to ensure authors understand the costs associated with publication. Information about publication fees is available at https://genomicpress.kglmeridian.com/view/journals/genpsych/genpsych-overview.xml/about

The academic and scholarly event announcements from non-profit organizations that appear in our journal are either provided at cost or offered free of charge as a service to the academic community. These announcements do not constitute a significant revenue source and are primarily included as a service to our readership.

15. Advertising Policy

Genomic Psychiatry maintains a restricted advertising policy that only accepts announcements from non-profit organizations for academic and scholarly events. We do not accept any commercial advertising. This selective approach ensures that any advertisements appearing on our website or in our publications are directly relevant to our academic audience and aligned with our scholarly mission. All such non-profit academic announcements are clearly distinguished from editorial content and are not related in any way to editorial decision-making. Our advertising policy is publicly available on our website to ensure complete transparency.

16. Ownership and Management

Genomic Psychiatry is published by Genomic Press, a specialized academic publisher focused on advancing open scientific communication in medicine and biosciences. Complete information about our ownership structure and management team is available on our website.

17. Contact Information

Editorial Office: Complete contact information for editorial inquiries is available on our website.

Author Guidelines: Detailed submission requirements, article type descriptions, and formatting instructions are available in our comprehensive Author Instructions.

Manuscript Submission: All manuscripts should be submitted through our online Submission Portal.

For general correspondence and additional information, please visit our website or contact our editorial office directly at support@genomicpress.com.

18. Direct Marketing Policy

Genomic Psychiatry maintains ethical standards in all marketing and solicitation activities:

1. Targeted Communications: We only contact researchers whose work aligns with our journal's scope
2. Opt-out Mechanism: All marketing communications include clear unsubscribe options
3. No Spam: We do not engage in mass unsolicited emails or aggressive marketing tactics
4. Transparency: All communications clearly identify Genomic Press and the specific journal
5. Respect for Privacy: We do not share contact information with third parties
6. Professional Standards: All marketing materials accurately represent our journal's scope, standards, and processes
7. No Misleading Claims: We do not make exaggerated claims about impact factors, indexing, or publication timelines

The unique strengths and advantages of publishing your research in Genomic Psychiatry include rapid and personalized review, global dissemination of your work, press releases leading to worldwide access, fair cost, and a dedicated but broad focus on cutting-edge research in multiple areas, highlighting advances in genomics in the context of progress in multiple other areas.

Amplifying Your Research Impact

In today's digital landscape, scientific communication extends far beyond traditional academic channels. At Genomic Psychiatry, we have developed a proven strategy that has generated over 500 news stories in more than 10 languages within our first two months of publication. Our comprehensive approach ensures your work achieves maximum visibility while maintaining rigorous scientific integrity.

Global Distribution Through EurekAlert!

All newsworthy articles published in Genomic Psychiatry are distributed through EurekAlert!, the world's leading science news service operated by AAAS. EurekAlert! has specific eligibility guidelines that news releases must meet to be accepted and hosted on their platform. Rest assured that Genomic Press will cover all submission fees associated with your press release. However, please note that payment of these fees does not guarantee acceptance by EurekAlert!

Genomic Press’ recent success stories through EurekAlert! demonstrate the power of this approach:

• Multiple Sclerosis Research: 124 media outlets worldwide
• Depression Treatment Analysis: 88 media outlets across 10 languages
• Body Dysmorphic Disorder Study: 80+ global media outlets
• Liver X Receptor Research: Multiple languages including Lithuanian, French, Portuguese

Each newsworthy paper receives coverage through:

• EurekAlert! English language service (12,000+ journalists)
• Multiple language versions (Spanish, French, Chinese, Japanese, Arabic)
• Specialized scientific channels targeting specific research communities

Strategic Digital Dissemination

We leverage various social media platforms strategically:

• LinkedIn: Connect with industry leaders, potential collaborators, and research organizations
• X (formerly Twitter): Engage in real-time with the global scientific community
• Facebook: Reach broader academic audiences through established scientific groups
• Instagram: Transform complex concepts into visually engaging content
• YouTube: Share in-depth interviews and methodology explanations

Comprehensive Press Distribution

Beyond EurekAlert!, our press office maximizes impact through:

• International press release networks
• Specialized science media outlets
• Institutional press offices
• Scientific news services

The success of our approach is evident in the rapid global uptake of research published in Genomic Psychiatry. At Genomic Press, our goal is not simply to publicize your research, but to foster meaningful engagement within both academic circles and the broader scientific community, as demonstrated by our achievement of over 500 media stories across multiple languages in our first two months.